View in Other Languages

Alvogen

SEO:002250 ISIN:KR7002250009

Alvogen KoreaAlvogen is a global, privately owned pharmaceutical company focused on developing, manufacturing and selling generic, brand, over-the-counter brands (OTC) and biosimilar products for patients around the world.  The company has commercial operations in 35 countries with 2,300 employees and operates four manufacturing and development hubs in the U.S., Romania, Korea and Taiwan. North America is Alvogen's single largest market and other key markets include: South Korea, Russia, Taiwan, Romania, Hungary, Ukraine, Japan and China.

    

News

Alvogen Launches the First Generic Equivalent to Tamiflu(R) Capsules in the United States

🕔12/13/2016 9:21:21 AM 4511

Alvogen has launched the first generic equivalent to Tamiflu(R) (oseltamivir phosphate) capsules in the United States. Alvogen expects the generic equivalent to Tamiflu(R) capsules to deliver significant savings for patients and health providers of up to $500 million during this upcoming season. The product is available in three strengths (30 mg, 45 mg and 75 mg).

Read Full Article
###

48,006 COMPANY PROFILE VIEWS

  • This Page Viewed: (Last 7 Days: 80) (Last 30 Days: 376) (Since Published: 7776) 

Markets

Company Data

    Headquarters
  • 07326 13F. TWO IFC Bldg. 10
    Gukjegeumyung-ro, Yeongdeungpo-gu,
    Seoul
    Korea
  • Telephone
  • +82-2-2047-7700 
  • Principal Sector
  • Drugs & OTC 
  • Principal Industry
  • Healthcare 
  • Homepage
  • www.alvogen.com

Social Media